1. Progress toward an amplifiable metabolic label for DNA: conversion of 4-thiothymidine (4sT) to 5-methyl-2′-deoxycytidine and synthesis of a 4sT phosphorodiamidate prodrug
- Author
-
Victor W.T. Liu, Nicholas Rhind, Michael P. Moazami, Job Dekker, Jonathan K. Watts, Marlies E. Oomen, and Adam K. Hedger
- Subjects
0301 basic medicine ,chemistry.chemical_classification ,biology ,Chemistry ,Base pair ,Organic Chemistry ,General Chemistry ,Prodrug ,Catalysis ,In vitro ,Nucleobase ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,Biochemistry ,biology.protein ,Nucleotide ,Nucleoside ,Polymerase ,DNA - Abstract
The ability to metabolically label DNA in a way that produces a latent change from one nucleobase to another would create a signal that can be amplified by PCR — this in turn would allow studies of newly synthesized DNA using high-throughput sequencing. To function as an amplifiable metabolic label, a nucleotide analogue would need to be taken up by cells and incorporated into cellular DNA; after purification of DNA, it could be converted into a different nucleobase with a different base pairing pattern. We selected 4-thiothymidine (4sT) as a candidate metabolic label: 4sT is readily taken up by a large number of polymerases in vitro, and we present a method that allows 4sT to be converted into 5-methyl-2′-deoxycytidine (5mC) after incorporation into DNA. Encouraged by these results, we treated cells with 4sT nucleoside; however, we found that 4sT is not incorporated into DNA in bacterial, yeast, or mammalian cells to useful levels under the conditions we tested. A phosphorodiamidate prodrug of 4sTMP was successfully synthesized but did not measurably improve incorporation into cellular DNA.
- Published
- 2018
- Full Text
- View/download PDF